Skip to main content
Funding round pulls in $13M for NeoSync

A round of Series D financing has brought in $13 million for Boston-based clinical-stage firm NeoSync. The proceeds will be used to fund a registration study of the company's NeoSync-EEG Synchronized TMS, or NEST, technology involving patients with treatment-resistant depression, as well as to prepare for the technology's commercial launch.

Full Story: